Home / Market News / $PYXS

$PYXS news and market catalysts

The 21 most recent market catalysts affecting $PYXS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

21 catalysts 5 high impact 8 bullish 4 bearish Biotechnology
Nov 7, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Markets Maintains Outperform Rating and Raises Price Target for Pyxis Oncology
RBC Capital Markets reiterated its 'Outperform' rating for Pyxis Oncology and raised its price target to $7 from $6. This positive revision is driven by the company's advancement i…
Nov 6, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Adjusts Price Target on Pyxis Oncology to $7
Wedbush Securities adjusted its price target for Pyxis Oncology (PYXS) from $8 to $7, a 12.5% reduction. This change comes after the company's recent corporate and financial update…
Nov 5, 2026 Corporate Catalyst Neutral Impact 65
Pyxis Oncology Reports Third Quarter 2026 Financial Results
Pyxis Oncology released its third-quarter 2026 financial results, a standard quarterly disclosure for public companies. The key takeaway, however, is the emphasis on continued posi…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Pyxis Oncology Announces Late-Breaking Oral Presentation of Micvotabart Pelidotin Data
Pyxis Oncology is announcing that it will present late-breaking Phase 1 clinical data for its drug candidate, micvotabart pelidotin (MICVO), at a major scientific symposium. This i…
Sep 30, 2026 Corporate Catalyst Bearish Impact 85
Pyxis Oncology shares are trading lower after the company announced the pricing of its $110 million offering of 36,047,919 shares at $2.90 with common warrants for 49,310,352 shares at a $3.50 exercise price.
The primary impact is negative for Pyxis Oncology due to significant share dilution from the offering. The pricing at $2.90, below the current trading price, and the issuance of wa…
Sep 30, 2026 Corporate Catalyst Neutral Impact 75
Pyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise Price
This headline indicates a significant capital raise for Pyxis Oncology, which is common for biotechnology companies needing funds for R&D and clinical trials. The offering of new s…
Sep 29, 2026 Corporate Catalyst Neutral Impact 75
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Pyxis Oncology is launching a public offering of its common stock and warrants to raise capital. This is a common strategy for clinical-stage biotechnology companies to fund expens…
Sep 29, 2026 Corporate Catalyst Neutral Impact 55
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
Pyxis Oncology has formally terminated its $150 million at-the-market (ATM) offering, which was established to sell common stock through Leerink Partners. The key takeaway is that …
Sep 10, 2026 Corporate Catalyst Bullish Impact 55
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Wedbush analyst Robert Driscoll maintained an 'Outperform' rating on Pyxis Oncology and raised the price target from $6 to $8. This action signals increased confidence from the ana…
Sep 10, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Pyxis Oncology and raised the price target from $7 to $8. This action signals continued analyst conf…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology announced updated Phase 1 trial data for its drug MICVO, touting 'promising efficacy and safety.' However, a William Blair analyst pointed out that 54% of patients e…
Sep 9, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19
Wells Fargo analyst Derek Archila has updated their outlook on Pyxis Oncology, raising the price target from $12 to $19 and reiterating an 'Overweight' rating. This action signals …
Sep 9, 2026 Corporate Catalyst Bearish Impact 85
Pyxis Oncology shares are trading lower after the company announced updated data from its ongoing global Phase 1 monotherapy study evaluating MICVO in patients with 2L+ R/M head and neck squamous cell carcinoma.
The headline indicates a significant negative reaction to updated clinical trial data for Pyxis Oncology's lead candidate, MICVO. While the specific details of the 'updated data' a…
Sep 9, 2026 Corporate Catalyst Bullish Impact 85
Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma
Pyxis Oncology's announcement of strong Phase 1 data for MICVO in a difficult-to-treat cancer like HNSCC is a major positive catalyst. The reported 36% confirmed objective response…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology's stock surged over 5% overnight following two key announcements. First, the appointment of Thomas Civik as permanent CEO and Chairman is a positive signal, given hi…
Sep 8, 2026 Corporate Catalyst Bullish Impact 85
Pyxis Oncology shares are trading higher after the company announced that it will present its updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma.
This headline represents a significant positive catalyst for Pyxis Oncology. Positive clinical data, especially from a Phase 1 study showing efficacy in a difficult-to-treat cancer…
Sep 8, 2026 Corporate Catalyst Neutral Impact 75
Pyxis Oncology To Present Updated Phase 1 MICVO Data In Head And Neck Cancer On A Live Webcast On September 9, 2026 At 7:30 a.m. ET
Pyxis Oncology is hosting a live webcast on September 9, 2026, to present updated Phase 1 clinical data for micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head…
Sep 8, 2026 Corporate Catalyst Neutral Impact 65
Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4
This 8-K filing announces that Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Mr. Civik …
Aug 20, 2026 Corporate Catalyst Neutral Impact 65
Pyxis Oncology Files Prospectus For Offering 39.2M Common Shares On Behalf Of Selling Shareholders
Pyxis Oncology has filed a prospectus for a secondary offering of up to 39.2 million common shares by existing selling shareholders. This is not a primary offering where the compan…
Aug 13, 2026 Corporate Catalyst Bearish Impact 92
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Pyxis Oncology announced its Q2 earnings, reporting a loss of $(0.40) per share, which fell short of analyst expectations by 14.29%. This miss is significant as it indicates the co…
Aug 3, 2026 Corporate Catalyst Neutral Impact 65
Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $12
Wells Fargo analyst Derek Archila initiated coverage on Pyxis Oncology (PYXS) with an 'Overweight' rating and a $12 price target. This event is significant because new analyst cove…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.